Company Description
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer.
CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
| Country | Germany |
| Founded | 2000 |
| IPO Date | Aug 14, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,172 |
| CEO | Alexander Zehnder |
Contact Details
Address: Friedrich-Miescher-Strasse 15 Tübingen, 72076 Germany | |
| Phone | 49 7071 9883 0 |
| Website | curevac.com |
Stock Details
| Ticker Symbol | CVAC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $16.00 |
| CIK Code | 0001809122 |
| CUSIP Number | N2451R105 |
| ISIN Number | NL0015436031 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alexander Zehnder M.B.A., M.D. | Chief Executive Officer, MD and Member of Management Board |
| Dr. Malte Greune Ph.D. | Chief Operating Officer, Member of Management Board and MD |
| Dr. Myriam Mendila M.D. | Chief Scientific Officer, Head of Research & Development, MD and Member of the Management Board |
| Dr. Ulrike Gnad-Vogt M.D., Ph.D. | Senior Vice President and Area Head of Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Nov 4, 2024 | 6-K | Report of foreign issuer |
| Nov 4, 2024 | 6-K | Report of foreign issuer |
| Sep 27, 2024 | 144 | Filing |
| Sep 25, 2024 | 144 | Filing |
| Sep 13, 2024 | 6-K | Report of foreign issuer |
| Sep 12, 2024 | 6-K | Report of foreign issuer |
| Sep 9, 2024 | 6-K | Report of foreign issuer |
| Aug 15, 2024 | 6-K | Report of foreign issuer |